Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at freezer (-20°C) for long term storage
Synonyms
AG 013736-d3; N-(Methyl-d3)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90 %
Hazard Compound
No -Refer MSDS for accurate information
Axitinib-d3 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Axitinib-d3 usage and description
Axitinib D3 is a deuterated version of Axitinib, which is a potent inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. It is primarily used as a targeted therapy for the treatment of advanced renal cell carcinoma, which is a type of kidney cancer. Axitinib D3 works by blocking the proteins that help cancer cells grow and form new blood vessels, which are necessary for their survival and spread throughout the body.
The chemical structure of Axitinib D3 is similar to that of Axitinib, with the addition of three deuterium atoms. Deuterium is a stable isotope of hydrogen that has a higher atomic mass, which can result in slower metabolism and longer half-life in the body. This modification can potentially improve the pharmacokinetics and efficacy of Axitinib D3, as well as reduce potential side effects.
Axitinib D3 is administered orally in the form of tablets, usually twice a day with or without food. The dosage may vary depending on the patient's medical condition, body weight, and other factors. It is important to follow the prescribed regimen and notify the healthcare provider of any adverse reactions or interactions with other medications.
In summary, Axitinib D3 is a deuterated version of Axitinib that is used as a targeted therapy for the treatment of advanced renal cell carcinoma. It works by blocking the growth and spread of cancer cells by inhibiting vascular endothelial growth factor receptors. The addition of deuterium atoms can potentially improve the pharmacokinetics and efficacy of Axitinib D3.
